Information TRx0237 (LMTX) mesylate TRx 0237 mesylate (LMTX, Hydromethylthionine) is a second-generation tau protein aggregation inhibitor for the treatment of Alzheimer's disease (AD) and frontotemporal dementia. Targets tau protein aggregation In vitro TRx 0237 (LMTX™) is a second-generation tau protein aggregation inhibitor for the treatment of Alzheimer\'s disease (AD) and frontotemporal dementia. It is a purified forms of Methylene Blue, an old drug that predates the FDA and is being widely used in Africa for the treatment for malaria as well as for methemoglobinemia and other conditions. An in vitro study showed the ability of TRx 0237 in disrupting PHFs(paired helical filaments) isolated from Alzheimer\'s Disease brain tissues at the concentration at 0.16 μM. In vivo TRx 0237 dose-dependently rescues the learning impairment and restores behavioral flexibility in a spatial problem-solving water-maze task in L1 (minimum effective dose: 9 mg MT/kg for TRx0237) and correctes motor learning in L66 (effective doses: 4 mg MT/kg). It reduces the number of tau-reactive neurons, particularly in the hippocampus and entorhinal cortex in L1 and in a more widespread manner in L66.